A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Mise à jour : Il y a 4 ans
Référence : NCT00866281

Femme et Homme

Extrait

This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory acute leukemias that may benefit from administration of midostaurin, including MLL-rearranged ALL and FLT3 positive AML.


Critère d'inclusion

  • Acute Myeloid Leukemia ,Acute Lymphoblastic Leukemia


Liens